Dermavant Sciences, a dermatology-focused subsidiary of Roivant Sciences, appointed Philip M. Brown, MD, JD, as Chief Medical Officer. With more than 25 years of experience leading clinical development programs, Dr. Brown most recently served as head of global pharmaceutical drug development at Galderma, the pharmaceutical subsidiary of Nestlé Skin Health.

“It is a privilege to join the Dermavant team,” says Dr. Brown. “Dermavant has one of the most innovative medical dermatology pipelines in the industry, and I look forward to overseeing the advancement of investigational medicines which address true unmet needs.”

Prior to joining Galderma, Dr. Brown served as senior vice president of clinical development at Lexicon Pharmaceuticals, a publicly-traded biopharmaceutical company engaged in the discovery and development of treatments using proprietary gene knockout technology. Dr. Brown also has served in other clinical development leadership roles in both public and private biotechnology companies. He received his MD from Texas Tech University Health Science Center School of Medicine, his JD from the University of Texas School of Law, and his BA from Hendrix College.

“Phil joins Dermavant at a critical time in the company’s evolution, as we prepare to initiate our Phase 3 program evaluating tapinarof in psoriasis,” says Todd Zavodnick, Chief Executive Officer of Dermavant. “Phil has the expertise and the judgment necessary to take tapinarof forward while simultaneously advancing our pipeline for other prevalent skin conditions.”